Health
Novo to Sell Weight-Loss Drug Wegovy Directly to Patients
This article is for subscribers only.
Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.
The Danish drugmaker launched NovoCare Pharmacy on Wednesday and said it will provide all doses of Wegovy drug at a reduced cost of $499 a month to cash-paying patients. The offer is for uninsured patients or those with commercial insurance who do not have coverage for obesity medicines, according to a statement.